期刊
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE
卷 8, 期 6, 页码 891-899出版社
ELSEVIER
DOI: 10.1016/j.nano.2011.10.014
关键词
Ovarian cancer; Lapatinib; Paclitaxel; Nanocapsules; Sonication-assisted Layer-by-Layer
资金
- Italian Ministry of University and Research (MIUR) through FIRB [RBLA03ER38]
- Con il contributo del Ministero degli Affari Esteri (MAE), Direzione Generale per la promozione e la Cooperazione Sociale (Italy - USA Large Scale Bilateral Project Nano-trasportatori per la terapia del cancro)
- ARTI strategic project Development and realization of bio-chip for molecular diagnostic and categorization of human pathogenic viruses (HPV, HCV) of Apulia Region [PS105]
The sonication-assisted layer-by-layer (SLBL) technology was developed to combine necessary factors for an efficient drug-delivery system: (i) control of nanocolloid size within 100 - 300 nm, (ii) high drug content (70% wt), (iii) shell biocompatibility and biodegradability, (iv) sustained controlled release, and (v) multidrug-loaded system. Stable nanocolloids of Paclitaxel (PTX) and lapatinib were prepared by the SLBL method. In a multidrug-resistant (MDR) ovarian cancer cell line, OVCAR-3, lapatinib/PTX nanocolloids mediated an enhanced cell growth inhibition in comparison with the PTX-only treatment. A series of in vitro cell assays were used to test the efficacy of these formulations. The small size and functional versatility of these nanoparticles, combined with their ability to incorporate various drugs, indicates that lapatinib/PTX nanocolloids may have in vivo therapeutic applications. From the Clinical Editor: The efficacy of Lapatinib/Paclitaxel polyelectrolyte nanocapsules is described in this study in cell cultures of multidrug-resistant ovarian cancer. If in vivo studies also result in similar efficacy and low toxicity, this may represent a viable avenue to address such malignancies. (C) 2012 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据